NASDAQ:NVCR NovoCure (NVCR) Stock Forecast, Price & News $17.59 -0.19 (-1.07%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$17.14▼$17.8850-Day Range$17.59▼$40.5752-Week Range$17.14▼$120.03Volume1.37 million shsAverage Volume2.73 million shsMarket Capitalization$1.88 billionP/E RatioN/ADividend YieldN/APrice Target$52.38 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability NovoCure MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside197.8% Upside$52.38 Price TargetShort InterestBearish9.55% of Float Sold ShortDividend StrengthN/ASustainability-1.15Upright™ Environmental ScoreNews Sentiment1.07Based on 6 Articles This WeekInsider TradingSelling Shares$31,639 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.07) to ($2.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector158th out of 965 stocksSurgical & Medical Instruments Industry25th out of 95 stocks 4.3 Analyst's Opinion Consensus RatingNovoCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $52.38, NovoCure has a forecasted upside of 197.8% from its current price of $17.59.Amount of Analyst CoverageNovoCure has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.55% of the float of NovoCure has been sold short.Short Interest Ratio / Days to CoverNovoCure has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in NovoCure has recently decreased by 1.81%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldNovoCure does not currently pay a dividend.Dividend GrowthNovoCure does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNovoCure has received a 68.17% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Brain cancer medication", and "Cabozantinib" products. See details.Environmental SustainabilityThe Environmental Impact score for NovoCure is -1.15. Previous Next 3.4 News and Social Media Coverage News SentimentNovoCure has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NovoCure this week, compared to 4 articles on an average week.Search InterestOnly 23 people have searched for NVCR on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.MarketBeat Follows19 people have added NovoCure to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovoCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,639.00 in company stock.Percentage Held by InsidersOnly 5.67% of the stock of NovoCure is held by insiders.Percentage Held by Institutions84.11% of the stock of NovoCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for NovoCure are expected to decrease in the coming year, from ($2.07) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovoCure is -10.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovoCure is -10.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovoCure has a P/B Ratio of 4.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About NovoCure (NASDAQ:NVCR) StockNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Read More NVCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVCR Stock News HeadlinesAugust 28, 2023 | marketbeat.com3M, Boston Scientific rise; Abcam, NovoCure fall, Monday, 8/28/2023Stocks that are trading heavily or have substantial price changes on Monday: 3M, Boston Scientific rise; Abcam, NovoCure fallSeptember 19, 2023 | msn.com3 Things About NovoCure That Smart Investors KnowSeptember 22, 2023 | Chaikin Analytics (Ad)This is the #1 Stock to Buy for the AI Tidal WaveMarc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.September 18, 2023 | finance.yahoo.comShould You Hold NovoCure Limited (NVCR)?September 18, 2023 | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 8, 2023 | finance.yahoo.comNovocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung CancerSeptember 4, 2023 | finance.yahoo.comDown 31% in 1 Day, What's Next for NovoCure Stock?August 31, 2023 | msn.comIs NovoCure's Stock Headed for a Free Fall?September 22, 2023 | Chaikin Analytics (Ad)"This Could be the Biggest Stock Story of 2023"A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.August 31, 2023 | msn.comWhy Novocure Stock Fell 24.4% This WeekAugust 29, 2023 | businesswire.comNovocure Announces The Lancet Oncology Publishes Primary Data from Phase 3 LUNAR Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based ...August 29, 2023 | markets.businessinsider.comWhat 11 Analyst Ratings Have To Say About NovoCureAugust 29, 2023 | benzinga.comWhat's Going On With NovoCure Stock Today?August 29, 2023 | seekingalpha.comHC Wainwright cuts NovoCure to neutral in wake of failed studyAugust 29, 2023 | seekingalpha.comNovoCure: TTFields' Ovarian Trial Short-Circuits (Rating Downgrade)August 29, 2023 | msn.comNovocure Shares Plunge After Its Ovarian Cancer Treatment Fails to Meet GoalAugust 28, 2023 | msn.comWhy Is Cancer Focused-Novocure's Stock Plunging Today?August 28, 2023 | finance.yahoo.comNovoCure (NVCR): A Smart Investment or a Value Trap? An In-Depth ExplorationAugust 28, 2023 | finance.yahoo.comNovoCure Ltd (NVCR): A Deep Dive into Its Performance PotentialAugust 28, 2023 | finance.yahoo.comNovocure Plummets 38% After Its Cancer Treatment Fails In Ovarian CancerAugust 28, 2023 | investorplace.comWhy Is Novocure (NVCR) Stock Down 30% Today?August 28, 2023 | finance.yahoo.com3M, XPeng, Hawaiian Electric Industries rise premarket; Novocure slidesAugust 28, 2023 | msn.comNovocure's cancer therapy fails to meet main goal in late-stage trialAugust 28, 2023 | finance.yahoo.comNovocure Plummets 34% After Its Cancer Treatment Fails In Ovarian CancerAugust 28, 2023 | news.yahoo.comNovocure adding penthouse to oncology company's new headquarters in PortsmouthAugust 26, 2023 | finance.yahoo.comNovoCure Limited (NVCR) Interactive Stock Chart - Yahoo FinanceAugust 25, 2023 | finance.yahoo.comCould NovoCure Stock Help You Become a Millionaire?See More Headlines Receive NVCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovoCure and its competitors with MarketBeat's FREE daily newsletter. Email Address NVCR Company Calendar Last Earnings7/27/2023Today9/22/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVCR CUSIPN/A CIK1645113 Webwww.novocure.com Phone441534756700FaxN/AEmployees1,320Year FoundedN/APrice Target and Rating Average Stock Price Forecast$52.38 High Stock Price Forecast$102.00 Low Stock Price Forecast$25.00 Forecasted Upside/Downside+197.8%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,530,000.00 Net Margins-34.35% Pretax Margin-31.71% Return on Equity-40.21% Return on Assets-14.84% Debt Debt-to-Equity Ratio1.36 Current Ratio7.10 Quick Ratio6.88 Sales & Book Value Annual Sales$537.84 million Price / Sales3.49 Cash FlowN/A Price / Cash FlowN/A Book Value$4.20 per share Price / Book4.19Miscellaneous Outstanding Shares106,620,000Free Float100,571,000Market Cap$1.88 billion OptionableOptionable Beta0.62 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. William F. Doyle (Age 61)Exec. Chairman Comp: $1.52MMr. Asaf Danziger (Age 57)Pres, CEO & Director Comp: $1.7MMs. Ashley Cordova (Age 43)Chief Financial Officer Comp: $933.39kMr. Wilhelmus C. M. Groenhuysen (Age 65)Chief Operating Officer Comp: $1.01MMr. Pritesh Shah (Age 44)Chief Growth Officer Comp: $810.6kMr. Frank LeonardPres of CNS Cancers U.S.Prof. Yoram Palti M.D. (Age 85)Ph.D., Founder & CTO Dr. Moshe Giladi Ph.D.Chief Science OfficerMs. Ingrid GoldbergVP of Investor RelationsMr. Barak Ben Arye (Age 47)Gen. Counsel More ExecutivesKey CompetitorsAtriCureNASDAQ:ATRCAlphatecNASDAQ:ATECPROCEPT BioRoboticsNASDAQ:PRCTTandem Diabetes CareNASDAQ:TNDMLeMaitre VascularNASDAQ:LMATView All CompetitorsInsiders & InstitutionsWilhelmus Cm GroenhuysenSold 294 sharesTotal: $6,415.08 ($21.82/share)Pritesh ShahSold 273 sharesTotal: $5,956.86 ($21.82/share)Ashley CordovaSold 883 sharesTotal: $19,267.06 ($21.82/share)Wolverine Trading LLCBought 12,900 shares on 8/23/2023Ownership: 0.000%California State Teachers Retirement SystemSold 4,024 shares on 8/21/2023Ownership: 0.148%View All Insider TransactionsView All Institutional Transactions NVCR Stock - Frequently Asked Questions Should I buy or sell NovoCure stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NVCR shares. View NVCR analyst ratings or view top-rated stocks. What is NovoCure's stock price forecast for 2023? 9 brokers have issued 1 year target prices for NovoCure's stock. Their NVCR share price forecasts range from $25.00 to $102.00. On average, they anticipate the company's share price to reach $52.38 in the next twelve months. This suggests a possible upside of 197.8% from the stock's current price. View analysts price targets for NVCR or view top-rated stocks among Wall Street analysts. How have NVCR shares performed in 2023? NovoCure's stock was trading at $73.35 on January 1st, 2023. Since then, NVCR shares have decreased by 76.0% and is now trading at $17.59. View the best growth stocks for 2023 here. When is NovoCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our NVCR earnings forecast. How were NovoCure's earnings last quarter? NovoCure Limited (NASDAQ:NVCR) posted its quarterly earnings results on Thursday, July, 27th. The medical equipment provider reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.04. The medical equipment provider had revenue of $126.05 million for the quarter, compared to the consensus estimate of $124.25 million. NovoCure had a negative net margin of 34.35% and a negative trailing twelve-month return on equity of 40.21%. The business's revenue for the quarter was down 10.5% compared to the same quarter last year. During the same period last year, the firm posted ($0.23) EPS. What ETFs hold NovoCure's stock? ETFs with the largest weight of NovoCure (NASDAQ:NVCR) stock in their portfolio include BlueStar Israel Technology ETF (ITEQ), VanEck Israel ETF (ISRA), Principal Healthcare Innovators ETF (BTEC), Invesco NASDAQ Next Gen 100 ETF (QQQJ), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares U.S. Medical Devices ETF (IHI).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What is Asaf Danziger's approval rating as NovoCure's CEO? 17 employees have rated NovoCure Chief Executive Officer Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among the company's employees. What other stocks do shareholders of NovoCure own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), Salesforce (CRM) and Block (SQ). What is NovoCure's stock symbol? NovoCure trades on the NASDAQ under the ticker symbol "NVCR." Who are NovoCure's major shareholders? NovoCure's stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (10.68%), Capital International Investors (8.26%), Baillie Gifford & Co. (8.18%), BlackRock Inc. (7.62%), Geode Capital Management LLC (1.37%) and Credit Suisse AG (0.77%). Insiders that own company stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle. View institutional ownership trends. How do I buy shares of NovoCure? Shares of NVCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is NovoCure's stock price today? One share of NVCR stock can currently be purchased for approximately $17.59. How much money does NovoCure make? NovoCure (NASDAQ:NVCR) has a market capitalization of $1.88 billion and generates $537.84 million in revenue each year. The medical equipment provider earns $-92,530,000.00 in net income (profit) each year or ($1.65) on an earnings per share basis. How many employees does NovoCure have? The company employs 1,320 workers across the globe. How can I contact NovoCure? NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The official website for the company is www.novocure.com. The medical equipment provider can be reached via phone at 441534756700 or via email at investorinfo@novocure.com. This page (NASDAQ:NVCR) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.